Aequus Pharmaceuticals (TSE:AQS) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Aequus Pharmaceuticals has secured an exclusive deal with Advanced Ophthalmic Innovations to distribute the PAUL® glaucoma drainage device in Canada, a product already approved in over 40 countries. The agreement enhances Aequus’s ophthalmology portfolio and leverages its existing sales infrastructure, aiming for a Canadian launch in Q4. The PAUL® device offers an innovative treatment option for patients with moderate to severe glaucoma, aligning with Aequus’s commitment to improving eyecare.
For further insights into TSE:AQS stock, check out TipRanks’ Stock Analysis page.